TPG, the American private equity firm, has completed a £300m acquisition of Optum UK, the parent company of EMIS, the software provider that manages electronic patient records for more than half of England's GP practices. The deal hands a US investment firm control over infrastructure that underpins the day-to-day running of primary care across the country.

EMIS functions as the plumbing of English general practice. Its systems hold the records of millions of patients, tracking prescriptions, referrals, test results and consultation histories that GPs rely on to treat patients safely. The acquisition was cleared under the National Security and Investment Act 2021, a statute designed to screen foreign takeovers of sensitive infrastructure. Yet the transaction proceeded with little public attention, and few outside the health technology sector appear to have registered the change of ownership before it was finalised.

That lack of visibility has become a central complaint. The Doctors' Association UK has raised concerns that a private equity firm, whose primary obligation is to deliver returns to its investors, now sits at the centre of a system that handles some of the most sensitive information the state holds about its citizens. The organisation has questioned whether commercial incentives can be reconciled with the duty of care owed to patients whose data is being managed.

Politicians have echoed that unease. The Liberal Democrats' health spokesperson criticised the absence of parliamentary scrutiny before the deal went through, arguing that ministers should be investing in British technology companies rather than allowing critical health infrastructure to pass into the hands of US firms. Health policy experts have made a similar point in broader terms, warning that private equity's expansion into the health service has outpaced the regulatory framework meant to govern it. The concern is not confined to this transaction alone; it reflects a pattern that has developed with limited public debate.

TPG's international record has added weight to those objections. Investigations into Evercare, a healthcare group in Kenya backed by TPG's Rise Fund, have alleged that its hospitals pursued aggressive billing practices. Some patients were reportedly left with severe debt, and in certain cases were asked to provide land deeds as collateral against unpaid bills. Critics of the EMIS acquisition have pointed to that history as grounds for closer examination of TPG's approach to healthcare assets more broadly.

TPG has rejected the characterisation of its conduct in Kenya. The firm says it has invested more than $100m to strengthen clinical governance, improve accessibility and protect patient rights at the hospitals in question, and disputes claims that its practices have harmed patients.

On the question of NHS data, TPG and EMIS have both sought to reassure the public that nothing has changed. Both companies state that existing data protections remain fully in place, and TPG has been explicit that it cannot access or make use of NHS patient records held on EMIS systems. Legal, contractual and operational safeguards governing the data, they say, continue to apply exactly as they did before the acquisition, and oversight of how the information is used remains with the NHS and its regulators rather than with TPG.

The Department of Health and Social Care has so far declined to comment on the transaction. Its silence has done little to settle the debate over how far private capital should be allowed into the systems that hold the country's health data, and how much scrutiny such deals ought to receive before they are approved. For now, EMIS continues to operate as before, its ownership changed but its function unaltered. Whether that reassurance proves durable will depend on how the arrangement is tested over time, and on whether Parliament decides the current level of oversight was ever sufficient.

‍